Molecular Characterization of NS5A Resistance Associated Substitutions after Failure of Sofosbuvir/Daclatasvir Combination Therapy in Chronic Hepatitis C Genotype 4a Infected Egyptian Patients Compared to Direct-Acting Antiviral Agent (DAA)-Naïve Sequences

2018 ◽  
Vol 27 (4) ◽  
pp. 157-164
Author(s):  
Ramadan , Raghdaa A. ◽  
Mohammed , Ahmed S. ◽  
Fakhr , Ahmed E.
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Combination Therapy ◽  
Molecular Characterization ◽  
Chronic Hepatitis C ◽  
Antiviral Agent ◽  
Direct Acting Antiviral ◽  
Egyptian Patients ◽  
Direct Acting

scholarly journals Factors Attenuating Zinc Deficiency Improvement in Direct-Acting Antiviral Agent-Treated Chronic Hepatitis C Virus Infection

Nutrients ◽  
2018 ◽  
Vol 10 (11) ◽  
pp. 1620 ◽  
Author(s):  
Yi-Ling Ko ◽  
Daisuke Morihara ◽  
Kumiko Shibata ◽  
Ryo Yamauchi ◽  
Hiromi Fukuda ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Zinc Deficiency ◽  
Dietary Habits ◽  
Serum Zinc ◽  
Antiviral Agent ◽  
Zinc Status ◽  
Direct Acting Antiviral ◽  
Direct Acting

Zinc deficiency is frequently observed in chronic liver diseases. However, no studies have focused on the zinc status in chronic hepatitis C (HCV)-infected patients receiving direct-acting antiviral agents (DAAs). In this retrospective study, we assessed the serum zinc status in DAA-treated HCV patients with sustained virologic response for over two years (Zn-2y). Ninety-five patients were enrolled, whose baseline characteristics and blood parameters at DAA therapy initiation were collected. Baseline Zn < 65 µg/dL (odds ratio (OR) = 10.56, p < 0.001) and baseline uric acid (UA) > 5.5 mg/dL (OR = 9.99, p = 0.001) were independent risk factors for Zn-2y deficiency. A decision-tree algorithm classified low-baseline Zn and high-baseline UA as the first two variables, suggesting that baseline hypozincemia and hyperuricemia are prognosticators for long-term zinc deficiency. Baseline Zn was negatively correlated with the Fibrosis-4 (FIB-4) index, while baseline UA was significantly higher in habitual alcohol drinkers. In conclusion, serum zinc levels should be closely monitored, considering that zinc status improvement is related to liver fibrosis regression. Hyperuricemia indicates risks of developing metabolic disorders and subsequent zinc deficiency, for which an adjustment of personal lifestyle or dietary habits should be recommended clinically.

Thailand practice guideline for management of chronic hepatitis C 2018

2018 ◽  
Vol 1 (3) ◽  
pp. 50-60
Author(s):  
THASL Committee
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Practice Guideline ◽  
Treatment Strategies ◽  
Antiviral Agent ◽  
Hcv Treatment ◽  
Direct Acting Antiviral ◽  
The North ◽  
Direct Acting

Chronic hepatitis C is one of the important cause of chronic liver diseases leading to cirrhosis and hepatocellular carcinoma worldwide. The prevalence of chronic hepatitis C in Thailand is about 1 - 5% where the prevalence is higher in the north and northeastern. Treatment of chronic hepatitis C has been developed and markedly improved in the last 3 decades. Since the advanced development of direct acting antiviral agent (DAA), treatment of chronic hepatitis C has been much improved not only in the efficacy but also tolerability and safety. IFN-free DAA treatment become a standard therapy in many country including Thailand. Due to fast development of HCV treatment strategies, Thailand Association for the Study of the Liver Disease has recurrently developed practice guideline for management of chronic hepatitis C in order to practically guide and to significantly improve HCV treatment in Thailand. The article reveals the detail of Thailand practice guideline for management of chronic hepatitis C 2018

scholarly journals Management of patients with chronic hepatitis C failing repeated courses of interferon‐free direct acting antiviral combination therapy

GastroHep ◽  
2019 ◽  
Vol 1 (2) ◽  
pp. 76-83 ◽  
Author(s):  
Karin Kozbial ◽  
Ramona Al‐Zoairy ◽  
Michael Gschwantler ◽  
Rudolf Stauber ◽  
Stephanie Hametner ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Combination Therapy ◽  
Chronic Hepatitis C ◽  
Direct Acting Antiviral ◽  
Direct Acting

scholarly journals Baseline thrombopoietin level is associated with platelet count improvement in thrombocytopenic chronic hepatitis C patients after successful direct-acting antiviral agent therapy

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Yen-Chun Chen ◽  
Ping-Hung Ko ◽  
Chi-Che Lee ◽  
Chih-Wei Tseng ◽  
Kuo-Chih Tseng
Keyword(s):  
Chronic Hepatitis ◽  
Platelet Count ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Characteristic Curve ◽  
Antiviral Agents ◽  
Antiviral Agent ◽  
Direct Acting Antiviral ◽  
Direct Acting ◽  
Improvement Ratio

Abstract Background Thrombocytopenia can rapidly improve in chronic hepatitis C (CHC) patients receiving direct-acting antiviral agents (DAA). The role of baseline (BL) thrombopoietin (TPO) in this phenomenon is unclear. Methods From June 2016 to February 2019, a total of 104 CHC patients receiving DAA, with a sustained virologic response and BL thrombocytopenia, at Dalin Tzu Chi Hospital, were enrolled in this retrospective study. Significant platelet count improvement and platelet count improvement ratio were analyzed for correlation with BL TPO. Results This cohort included 40 men (38.5%). Seventy-two (69.2%) patients had advanced fibrosis. The platelet count [median (range)] increased from 110.5 (32–149) × 103/µL at BL to 116.5 (40–196) and 118.0 (35–275) × 103/µL at end of treatment (EOT) and 12 weeks after EOT (P12), respectively, (EOT vs. BL, P < 0.001; P12 vs. BL, P < 0.001). BL TPO was positively correlated with significant platelet count improvement (P < 0.001), platelet count improvement ratio at EOT (P = 0.004), and P12 (P < 0.001). The area under the receiver operating characteristic curve and optimal cutoffs (pg/ml) were 0.77 (95% confidence interval, 0.67–0.86) and 120, respectively, for significant platelet count improvement prediction. The sensitivity, specificity, and accuracy were 88.6%, 71.7%, and 78.8%, respectively. Conclusions BL TPO level might be a useful marker for predicting significant platelet count improvement in thrombocytopenic patients after successful DAA therapy.

Safety, efficacy and cost of two direct‐acting antiviral regimens: A comparative study in chronic hepatitis C Egyptian patients

2019 ◽  
Vol 45 (3) ◽  
pp. 539-546
Author(s):  
Abdel‐Hameed Ibrahim Mohammed Ebid ◽  
Osama Ashraf Ahmed ◽  
Sara Hassan Agwa ◽  
Sara Mohamed Abdel‐Motaleb ◽  
Amira Mohamed Elsawy ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Comparative Study ◽  
Chronic Hepatitis C ◽  
Direct Acting Antiviral ◽  
Egyptian Patients ◽  
Direct Acting

scholarly journals Baseline Thrombopoietin Level is Associated with Platelet Count Improvement in Thrombocytopenic Chronic Hepatitis C Patients After Direct-Acting Antiviral Agent Therapy

2020 ◽  
Author(s):  
Yen-Chun Chen ◽  
Ping-Hung Ko ◽  
Chi-Che Lee ◽  
Chih-Wei Tseng ◽  
Kuo-Chih Tseng
Keyword(s):  
Chronic Hepatitis ◽  
Platelet Count ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Characteristic Curve ◽  
Antiviral Agents ◽  
Antiviral Agent ◽  
Direct Acting Antiviral ◽  
Direct Acting ◽  
Improvement Ratio

Abstract Background Thrombocytopenia can rapidly improve in chronic hepatitis C (CHC) patients receiving direct-acting antiviral agents (DAA). The role of baseline (BL) thrombopoietin (TPO) in this phenomenon is unclear. Methods From June 2016 to February 2019, a total of 104 CHC patients receiving DAA, with a sustained virologic response and BL thrombocytopenia, at Dalin Tzu Chi Hospital, were enrolled in this retrospective study. Significant platelet count improvement and platelet count improvement ratio were analyzed for correlation with BL TPO. Results This cohort included 40 men (38.5%). Seventy-two (69.2%) patients had advanced fibrosis. The platelet count [median (range)] increased from 110.5 (32–149) × 103/µL at BL to 116.5 (40–196) and 118.0 (35–275) × 103/µL at end of treatment (EOT) and 12 weeks after EOT (P12), respectively, (EOT vs. BL, P < 0.001; P12 vs. BL, P < 0.001).BL TPO was positively correlated with significant platelet count improvement (P < 0.001), platelet count improvement ratio at EOT (P = 0.004), and P12 (P < 0.001). The area under the receiver operating characteristic curve and optimal cutoffs (pg/ml) were 0.77 (95% confidence interval, 0.67–0.86) and 120, respectively, for significant platelet count improvement prediction. The sensitivity, specificity, and accuracy were 88.6%, 71.7%, and 78.8%, respectively. Conclusions BL TPO level might be a useful marker for predicting significant platelet count improvement in thrombocytopenic patients after successful DAA therapy.

Sign in / Sign up

Export Citation Format

Share Document